NICE recommends carfilzomib for restricted use in England and Wales

The National Institute for Health and Care Excellence (NICE) has published a final appraisal determination (FAD) recommending the use of carfilzomib (Kyprolis┬«) in combination with dexamethasone for myeloma patients at first relapse who have not previously received bortezomib (Velcade┬«). Carfilzomib will immediately be available to eligible patients in England via interim funding arrangements through the…

Details